Amniotic Fluid-Derived Mesenchymal Stem Cells Cut Short the Acuteness of Cisplatin-Induced Nephrotoxicity in Sprague-Dawley Rats

Al-Husseiny, Fatma; Sobh, Mohamed; Ashour, Rehab H.; Foud, Samah; Medhat, Tarek; El‐Gilany, Abdel‐Hady; Elghannam, Doaa M.; Abdel-Ghaffar, Hassan; Saad, Mohamed

doi:10.15283/ijsc.2016.9.1.70

Cited by 15 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In xenogeneic studies, good results in terms of survival rate, renal function and morphology were achieved through the application of different types of hMSC, such as hBM-MSC ( 195 , 196 ), hAFSC ( 182 , 192 ), hESC-MP ( 190 ), hUC-MSC ( 32 , 179 , 187 , 189 ), hUCB-MSC ( 31 , 85 ). Recently, hASC have become the most widely used cell type in animal experiments, resulting in good treatment results in AKI ( 180 , 183 , 184 , 186 ).…”

Section: Msc Therapy In the Treatment Of Kidney Diseases: State Of Thmentioning

confidence: 99%

Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models

et al. 2018

View full text Add to dashboard Cite

Within the last years, the use of stem cells (embryonic, induced pluripotent stem cells, or hematopoietic stem cells), Progenitor cells (e.g., endothelial progenitor cells), and most intensely mesenchymal stromal cells (MSC) has emerged as a promising cell-based therapy for several diseases including nephropathy. For patients with end-stage renal disease (ESRD), dialysis or finally organ transplantation are the only therapeutic modalities available. Since ESRD is associated with a high healthcare expenditure, MSC therapy represents an innovative approach. In a variety of preclinical and clinical studies, MSC have shown to exert renoprotective properties, mediated mainly by paracrine effects, immunomodulation, regulation of inflammation, secretion of several trophic factors, and possibly differentiation to renal precursors. However, studies are highly diverse; thus, knowledge is still limited regarding the exact mode of action, source of MSC in comparison to other stem cell types, administration route and dose, tracking of cells and documentation of therapeutic efficacy by new imaging techniques and tissue visualization. The aim of this review is to provide a summary of published studies of stem cell therapy in acute and chronic kidney injury, diabetic nephropathy, polycystic kidney disease, and kidney transplantation. Preclinical studies with allogeneic or xenogeneic cell therapy were first addressed, followed by a summary of clinical trials carried out with autologous or allogeneic hMSC. Studies were analyzed with respect to source of cell type, mechanism of action etc.

show abstract

Section: Msc Therapy In the Treatment Of Kidney Diseases: State Of Thmentioning

confidence: 99%

Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Cells at passages 3–5 were trypsinized with 0.25% trypsin–EDTA solution, washed with phosphate-buffered saline (PBS), counted and incubated at room temperature for 30 min in the dark, with monoclonal phycoerythrin (PE)-conjugated antibody for CD45 (Abcam, ab23396, UK), monoclonal fluorescein isothiocyanate (FITC)-conjugated antibody for CD90 (Anti-Thy1.1) (Abcam, ab225, UK), and the monoclonal FITC-conjugated antibody for OCT4 antibody (Abcam, ab181557, UK). Immunofluorescence on the viable cells was analyzed using Becton Dickinson, FACS caliber flow cytometer equipped with Cell Quest software [ 12 , 14 ].…”

Section: Methodsmentioning

confidence: 99%

Potential effect of amniotic fluid-derived stem cells on hyperoxia-induced pulmonary alveolar injury

et al. 2022

View full text Add to dashboard Cite

Background With the widespread of Coronavirus Disease 2019 pandemic, in spite of the newly emerging vaccines, mutated strains remain a great obstacle to supportive and preventive measures. Coronavirus 19 survivors continue to face great danger of contacting the disease again. As long as no specific treatment has yet to be approved, a great percentage of patients experience real complications, including among others, lung fibrosis. High oxygen inhalation especially for prolonged periods is per se destructive to the lungs. Nevertheless, oxygen remains the first line support for such patients. In the present study we aimed at investigating the role of amniotic fluid-mesenchymal stem cells in preventing versus treating the hyperoxia-induced lung fibrosis in rats. Methods The study was conducted on adult albino rats; 5 pregnant female rats were used as amniotic fluid donors, and 64 male rats were randomly divided into two groups: Control group; where 10 rats were kept in normal atmospheric air then sacrificed after 2 months, and hyperoxia-induced lung fibrosis group, where 54 rats were exposed to hyperoxia (100% oxygen for 6 h/day) in air-tight glass chambers for 1 month, then randomly divided into the following 5 subgroups: Hyperoxia group, cell-free media-treated group, stem cells-prophylactic group, stem cells-treated group and untreated group. Isolation, culture and proliferation of stem cells were done till passage 3. Pulmonary function tests, histological examination of lung tissue under light and electron microscopes, biochemical assessment of oxidative stress, IL-6 and Rho-A levels, and statistical analysis of data were performed. F-test (ANOVA) was used for normally distributed quantitative variables, to compare between more than two groups, and Post Hoc test (Tukey) for pairwise comparisons. Results Labelled amniotic fluid-mesenchymal stem cells homed to lung tissue. Stem cells administration in the stem cells-prophylactic group succeeded to maintain pulmonary functions near the normal values with no significant difference between their values and those of the control group. Moreover, histological examination of lung tissues showed that stem cells-prophylactic group were completely protected while stem cells-treated group still showed various degrees of tissue injury, namely; thickened interalveolar septa, atelectasis and interstitial pneumonia. Biochemical studies after stem cells injection also showed decreased levels of RhoA and IL-6 in the prophylactic group and to a lesser extent in the treated group, in addition to increased total antioxidant capacity and decreased malondialdehyde in the stem cells-injected groups. Conclusions Amniotic fluid-mesenchymal stem cells showed promising protective and therapeutic results against hyperoxia-induced lung fibrosis as evaluated physiologically, histologically and biochemically.

show abstract

“…AFSC seem to protect tubular and glomerular cells by stimulating endogenous repair mechanisms, thus reducing inflammation and fibrosis . Other groups showed that these cells enhance recovery in 5/6 Nx models and cisplatin‐induced toxicity .…”

Section: Different Types Of Stem Cells and Preclinical Models Of Renamentioning

confidence: 99%

Concise Reviews: Stem Cells and Kidney Regeneration: An Update

Marcheque

Bussolati

Csete

et al. 2018

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Significant progress has been made to advance stem cell products as potential therapies for kidney diseases: various kinds of stem cells can restore renal function in preclinical models of acute and chronic kidney injury. Nonetheless this literature contains contradictory results, and for this reason, we focus this review on reasons for apparent discrepancies in the literature, because they contribute to difficulty in translating renal regenerative therapies. Differences in methodologies used to derive and culture stem cells, even those from the same source, in addition to the lack of standardized renal disease animal models (both acute and chronic), are important considerations underlying contradictory results in the literature. We propose that harmonized rigorous protocols for characterization, handling, and delivery of stem cells in vivo could significantly advance the field, and present details of some suggested approaches to foster translation in the field of renal regeneration. Our goal is to encourage coordination of methodologies (standardization) and long‐lasting collaborations to improve protocols and models to lead to reproducible, interpretable, high‐quality preclinical data. This approach will certainly increase our chance to 1 day offer stem cell therapeutic options for patients with all‐too‐common renal diseases. Stem Cells Translational Medicine 2019;8:82–92

show abstract

Amniotic Fluid-Derived Mesenchymal Stem Cells Cut Short the Acuteness of Cisplatin-Induced Nephrotoxicity in Sprague-Dawley Rats

Cited by 15 publications

References 28 publications

Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models

Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models

Potential effect of amniotic fluid-derived stem cells on hyperoxia-induced pulmonary alveolar injury

Concise Reviews: Stem Cells and Kidney Regeneration: An Update

Contact Info

Product

Resources

About